[Treatment of neonatal hyperthyroidism with calcium iopodate]

Arch Pediatr. 1996 Nov;3(11):1102-6. doi: 10.1016/s0929-693x(96)89517-0.
[Article in French]

Abstract

Background: Treatment of hyperthyroidism in those neonates born to mothers with Grave's disease is difficult. Calcium ipodate, an agent for oral cholecystography, inhibits extra-thyroid conversion of T3 to T4 and diminishes thyroid secretion.

Case reports: Two neonates with clinical manifestations and biological findings of hyperthyroidism were given calcium ipodate orally, 400 mg every 3 days, from day 26 to 50 for the first patient and from day 9 to 18 for the second in association with a beta blocker. Clinical manifestations disappeared within 2 days and circulating levels of T3 and T4 were normalized within 2-5 days.

Conclusions: This treatment was effective and well-tolerated in both patients and in three others previously reported; it should be confirmed in a larger number of patients and controlled by measuring levels of antibodies directed against thyrotropin-releasing hormone receptors in order to avoid relapse after cessation of treatment as seen in our second patient.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hyperthyroidism / drug therapy*
  • Infant, Newborn
  • Ipodate / administration & dosage
  • Ipodate / therapeutic use*
  • Propranolol
  • Triiodothyronine / antagonists & inhibitors*

Substances

  • Adrenergic beta-Antagonists
  • Triiodothyronine
  • Propranolol
  • Ipodate